• Aliases: ABX-EGF, MOAB ABX-EGF, rHuMAb-EGFr
    • A fully human mAb that binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR
    • First antibody to demonstrate the use of KRAS as a predictive biomarker
    • FDA approved for EGFR-expressing, mCRC
    • Recommended dose: 6 mg/kg IV infusion (over 60 or 90 minutes) every 14 days
    • Half-life: 7.5 days (range 4–11 days)
    • Common side effects: Dermatologic toxicity (rash, dermatitis acneiform, pruritus) (US box warning), infusion reactions (fevers, chills, bronchospasms) (US box warning), hypomagnesemia, paronychia, fatigue, nausea/vomiting, diarrhea
    Other topics in Targeted and Immunotherapy Agents